Psylink
Psylink is a Lithuanian biotech that uses genetically modified yeast cells to biosynthesize psychedelic compounds — including psilocybin, DMT, LSD, and mescaline — for clinical research institutions and pharmaceutical companies pursuing psychedelic therapeutics.
- Company typePrivate
- Founded2020
- HeadquartersVilnius, Lithuania
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Psylink does
Psylink is a Vilnius, Lithuania-based biotechnology company founded in 2020 that develops a yeast-cell biosynthesis platform for small-molecule psychedelic drug production. The company's core technology genetically modifies yeast cells to reconstruct the naturally occurring biosynthetic pathways of target molecules — including tryptamines (psilocybin, DMT, 5-MeO-DMT), ergolines (LSD), and phenethylamines (mescaline) — and is being extended to new molecular entities beyond naturally occurring compounds. A pending patent application (filed 2022-2023) covers the platform, and Psylink obtained a Schedule I substance license in 2021, enabling controlled-substance R&D in a GMP-compatible fermentation framework.
The company operates a B2B model targeting two primary segments: research institutions studying psychedelics for therapeutic applications, and pharmaceutical companies requiring GMP-compatible, scalable manufacturing of psychedelic drug substances for clinical trials. Psylink is pre-revenue, with stated revenue intent around licensing, contract manufacturing, or partnership deals with pharma companies. Distribution runs through direct enterprise engagement rather than traditional channels, supported by a minimal digital footprint (company website plus Instagram, LinkedIn, and Twitter profiles).
Psylink has raised approximately $729,303 in cumulative disclosed funding across a 2023 round led by FIRSTPICK and a 2025 round led by Coinvest Capital with BSV Ventures and FIRSTPICK participating. The company remains small (1-10 employees), founder-controlled, and at an early R&D and clinical-supply stage with no disclosed commercial customers, contracts, or product revenue.
Psylink firmographics
Firmographics- Name
- Psylink
- Website
- https://psylink.io
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Psylink is a Lithuanian biotech that uses genetically modified yeast cells to biosynthesize psychedelic compounds — including psilocybin, DMT, LSD, and mescaline — for clinical research institutions and pharmaceutical companies pursuing psychedelic therapeutics.
- Ownership category
- akta.pro rank
Psylink industry classification
Industry- Product category
- Biopharmaceutical Manufacturing
- NAICS
- Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)
- akta.pro secondary industries
- GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Psylink is headquartered
LocationHeadquarters
- HQ city
- Vilnius
- HQ country
- Lithuania
- HQ region
- Europe
Markets served
Psylink business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- B2B Drug Development Services: Pre-revenue biotech company developing biosynthesis platform for pharmaceutical applications. Revenue model likely based on licensing, contract manufacturing, or partnership deals with pharmaceutical companies for drug development.
Go-to-market motion1 record
Marketing channels4 records
Psylink product offering
Product offeringCore offering
Psylink develops and operates a proprietary yeast-based biosynthesis platform for the sustainable, scalable, and cost-effective production of psychedelic and other small-molecule drug substances. The company genetically modifies yeast cells to recreate biosynthetic pathways for naturally occurring molecules such as psilocybin, DMT, LSD, and mescaline, while also producing novel next-generation molecular entities. Outputs are intended for pharmaceutical companies and research institutions requiring GMP-compatible drug substances for clinical research and therapeutic development.
Product overview
Psylink is a biotechnology company offering a single unified biosynthesis platform for small-molecule drug development, with two complementary product lines: Classic Psychedelic Compounds (Tryptamines including Psilocybin and DMT, Ergolines including LSD, and Phenethylamines including Mescaline) produced via yeast-based biosynthesis, and New Molecular Entities representing next-generation novel compounds. The platform uses genetic modification of yeast cells to recreate naturally occurring biosynthetic pathways, providing sustainable, scalable, and GMP-compatible production of drug products for clinical research.
Differentiator
Problem solved
Functional benefit
Products and services
- Yeast-Based Biosynthesis Platform Proprietary yeast-based biosynthesis platform using genetically modified yeast cells to recreate naturally occurring biosynthetic pathways for producing psychedelic and other small-molecule drug substances. Serves pharmaceutical companies and academic research institutions needing GMP-compatible drug substances for clinical research and therapeutic development.
- Classic Psychedelic Compounds
Companies that use Psylink
Customer profileSegments2 records
Ideal customer profiles2 records
Psylink technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Psylink partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Research InstitutionscoreCollaboration with research institutions for novel indications (2023-2024) and manufacturing of additional drug products for clinical research. No specific institution names provided in source material.
Scale indicators1 record
Recent moves6 records
Expansion highlights4 records
Psylink competitors and assessment
Company assessmentEmerging players
- Small Pharma: Clinical-stage DMT-assisted therapy developer (SPL026) acquired by atai in 2024. A peer to Psylink's targeted tryptamine work and another potential API customer.
- Filament Health: Drug development and extraction company focused on naturally-derived psychedelic APIs. Comparable business model targeting GMP psychedelic drug substance manufacturing, though via plant extraction rather than biosynthesis.
- Psylo (formerly EmpathBio): Australian-based designer of novel psychedelic compounds with proprietary tryptamine analogs. Comparable emerging player in next-generation psychedelic drug development where Psylink's NME platform could be a manufacturing partner.
Broad incumbents
- GH Research: Irish clinical-stage company developing 5-MeO-DMT (GH001) for treatment-resistant depression. Direct overlap with Psylink's tryptamine platform and a potential supply/licensing counterparty.
- atai Life Sciences: Berlin-based mental health biotech platform holding multiple psychedelic drug developers (including psilocybin DMT programs). Potential customer for Psylink's API manufacturing and a benchmark for psychedelic biotech valuations.
- Amyris: Established industrial biotechnology company operating yeast fermentation platforms for ingredient manufacturing at scale. Comparable technology stack (engineered yeast strains, fermentation scale-up) though in different end markets (cosmetics, flavors) than Psylink.
- Cybin: Clinical-stage psychedelic therapeutics company developing deuterated psilocybin analog (CYB003). Comparable buyer/customer archetype for Psylink's psilocybin and next-gen tryptamine manufacturing capabilities.
- Compass Pathways: Clinical-stage psychedelic mental health company developing psilocybin therapy (COMP360). A potential customer of Psylink's manufacturing rather than a direct platform competitor, but the leading demand-side reference point for GMP psilocybin supply.
Direct peers
- Octarine Bio: Danish synthetic biology company engineering yeast for biosynthesis of cannabinoid and psychedelic compounds. Closest direct competitor to Psylink in yeast-based psychedelic API production with GMP ambitions.
- Hyasynth Biologicals: Montreal-based biotech using yeast fermentation to biosynthesize cannabinoids and other compounds including psilocybin. Directly comparable to Psylink as a yeast-based biosynthesis platform for psychoactive small molecules targeting pharmaceutical applications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Psylink social profiles
Digital presencePsylink financial estimates
Financial estimateRevenue estimate
Valuation estimate
Psylink leadership team
Management profileNumber of profiles
Profiles6 records
Psylink funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Psylink M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Psylink
What does Psylink do?
Psylink develops and operates a proprietary yeast-based biosynthesis platform for the sustainable, scalable, and cost-effective production of psychedelic and other small-molecule drug substances. The company genetically modifies yeast cells to recreate biosynthetic pathways for naturally occurring molecules such as psilocybin, DMT, LSD, and mescaline, while also producing novel next-generation molecular entities. Outputs are intended for pharmaceutical companies and research institutions requiring GMP-compatible drug substances for clinical research and therapeutic development.
Is Psylink a public or private company?
Psylink is a private company. It is classified as venture growth investor backed and is currently operating.
When was Psylink founded?
Psylink was founded in 2020. It employs 1 to 10 people.
Where is Psylink based?
Psylink is headquartered in Vilnius, Lithuania, in the Europe region.
How does Psylink make money?
One revenue line is on record: B2B Drug Development Services.
Who are Psylink's main competitors?
Emerging players on record are Small Pharma, Filament Health and Psylo (formerly EmpathBio). Broad incumbents are GH Research, atai Life Sciences, Amyris, Cybin and Compass Pathways. Direct peers are Octarine Bio and Hyasynth Biologicals.
Does Psylink have an API?
No public API is recorded for Psylink.
What industry is Psylink in?
Psylink's product category is Biopharmaceutical Manufacturing. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ). Its NAICS code is 325411 and its SIC code is 2833.